Aprea Therapeutics Inc (APRE) Finansal

Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of cancer therapeutics. The company is headquartered in Doylestown, Pennsylvania and currently employs 8 full-time employees. The company went IPO on 2019-10-03. The Company’s pipeline includes two clinical-stage synthetic lethality programs. Its lead programs are APR-1051, an oral, small-molecule inhibitor of WEE1 kinase, and ATRN-119, a small-molecule ATR inhibitor, both in clinical development for solid tumor indications. Its ATRN-119 is an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related (ATR). The ATR kinase is a master regulator of Deoxyribonucleic Acid (DNA) damage response, with roles in cell cycle control and DNA repair following replication stress. The company is evaluating potential combination opportunities within its pipeline, including research on the combination of ATRN-119 and APR-1051 that is supported by a Phase II SBIR grant from the National Cancer Institute. The company also has an early-stage program, in the lead optimization stage, for an undisclosed DNA-damage response (DDR) target.